Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 79Lymphoid 56Other hematologic neoplasm 13Myeloid 2Classical hematology 2CNS 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 107Specimen Handling 86pembrolizumab 77enzalutamide 59Nivolumab 57Gemcitabine 55Docetaxel 50Androgen Antagonists 44apalutamide 41Radiosurgery 41Prednisone 40Abiraterone Acetate 39darolutamide 37Cisplatin 36Biopsy 35Radiotherapy 33cabozantinib 31Carboplatin 29abiraterone 28Ipilimumab 28Pluvicto 26Leuprolide 25durvalumab 24X-Rays 23Radiation 23enfortumab vedotin 22acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19Standard of Care 19olaparib 18avelumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lenalidomide × Genitourinary × 90 days × Clear all
NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡